Critical illness polyneuropathy and myopathy: Clinical features, risk factors and prognosis

European Journal of Neurology

Volumn 13, Issue 11, 2006, Pages 1203-1212

  Visser, L H ^a  

^a CPRLab   (Netherlands)

Author keywords

Critical illness; Intensive care; Myopathy; Neuromuscular weakness; Polyneuropathy; Risk factors

Indexed keywords

ARTIFICIAL VENTILATION; CLINICAL FEATURE; CRITICAL ILLNESS; CRITICAL ILLNESS POLYNEUROPATHY AND MYOPATHY; DIFFERENTIAL DIAGNOSIS; DISABILITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTROPHYSIOLOGY; HOSPITALIZATION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; MORTALITY; MULTIPLE ORGAN FAILURE; MUSCLE WEAKNESS; MYOPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

BIOPSY; CRITICAL ILLNESS; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MUSCLE, SKELETAL; MUSCULAR DISEASES; NERVE TISSUE; POLYNEUROPATHIES; PROGNOSIS; RISK FACTORS;

EID: 33750051619     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2006.01498.x     Document Type: Review

References (61)

1. Lacomis D, Petrella JT, Giuliani MJ. Causes of neuromuscular weakness in the intensive care unit: a study of ninety-two patients. Muscle and Nerve 1998; 21: 610-617.
2. Hund E. Neurological complications of sepsis: critical illness polyneuropathy and myopathy. Journal of Neurology 2001; 248: 929-934.
3. De Jonghe B, Sharshar T, Lefaucheur JP et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002; 288: 2859-2867.
4. Bolton CF. Neuromuscular manifestations of critical illness. Muscle and Nerve 2005; 32: 140-163.
5. Bolton CF, Gilbert JJ, Hahn AF, Sibbald WJ. Polyneuropathy in critically ill patients. Journal of Neurology, Neurosurgery and Psychiatry 1984; 47: 1223-1231.
6. Op de Coul AA, Lambregts PC, Koeman J, van Puyenbroek MJ, Ter Laak HJ, Gabreels-Festen AA. Neuromuscular complications in patients given Pavulon (pancuronium bromide) during artificial ventilation. Clinical Neurology and Neurosurgery 1985; 87: 17-22.
7. Witt NJ, Zochodne DW, Bolton CF et al. Peripheral nerve function in sepsis and multiple organ failure. Chest 1991; 99: 176-184.
8. Bolton CF, Laverty DA, Brown JD, Witt NJ, Hahn AF, Sibbald WJ. Critically ill polyneuropathy: electrophysiological studies and differentiation from Guillain-Barre syndrome. Journal of Neurology, Neurosurgery and Psychiatry 1986; 49: 563-573.
9. Op de Coul AA, Verheul GA, Leyten AC, Schellens RL, Teepen JL. Critical illness polyneuromyopathy after artificial respiration. Clinical Neurology and Neurosurgery 1991; 93: 27-33.
10. Latronico N, Fenzi F, Recupero D et al. Critical illness myopathy and neuropathy. Lancet 1996; 347: 1579-1582.
11. de Letter MA, van Doorn PA, Savelkoul HF et al. Critical illness polyneuropathy and myopathy (CIPNM): evidence for local immune activation by cytokine-expression in the muscle tissue. Journal of Neuroimmunology 2000; 106: 206-213.
12. Bednarik J, Lukas Z, Vondracek P. Critical illness polyneuromyopathy: the electrophysiological components of a complex entity. Intensive Care Medicine 2003; 29: 1505-1514.
13. Deem S, Lee CM, Curtis JR. Acquired neuromuscular disorders in the intensive care unit. American Journal of Respiratory and Critical Care Medicine 2003; 168: 735-739.
14. Lacomis D, Zochodne DW, Bird SJ. Critical illness myopathy. Muscle and Nerve 2000; 23: 1785-1788.
15. de Letter MA, Schmitz PI, Visser LH et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Critical Care Medicine 2001; 29: 2281-2286.
16. Leijten FS, Harinck-de Weerd JE, Poortvliet DC, de Weerd AW. The role of polyneuropathy in motor convalescence after prolonged mechanical ventilation. JAMA 1995; 274: 1221-1225.
17. Van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. New England Journal of Medicine 2001; 345: 1359-1367.
18. Van den Berghe G, Schoonheydt K, Becx P, Bruyninckx F, Wouters PJ. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 2005; 64: 1348-1353.
19. Thiele RI, Jakob H, Hund E et al. Sepsis and catecholamine support are the major risk factors for critical illness polyneuropathy after open heart surgery. Thoracic and Cardiovascular Surgeon 2000; 48: 145-150.
20. Garnacho-Montero J, Madrazo-Osuna J, Garcia-Garmendia JL et al. Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Medicine 2001; 27: 1288-1296.
21. Latronico N, Peli E, Botteri M. Critical illness myopathy and neuropathy. Current Opinion in Critical Care 2005; 11: 126-132.
22. Berek K, Margreiter J, Willeit J, Berek A, Schmutzhard E, Mutz NJ. Polyneuropathies in critically ill patients: a prospective evaluation. Intensive Care Medicine 1996; 22: 849-855.
23. Tennila A, Salmi T, Pettila V, Roine RO, Varpula T, Takkunen O. Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis. Intensive Care Medicine 2000; 26: 1360-1363.
24. Druschky A, Herkert M, Radespiel-Troger M et al. Critical illness polyneuropathy: clinical findings and cell culture assay of neurotoxicity assessed by a prospective study. Intensive Care Medicine 2001; 27: 686-693.
25. Banwell BL, Mildner RJ, Hassall AC, Becker LE, Vajsar J, Shemie SD. Muscle weakness in critically ill children. Neurology 2003; 61: 1779-1782.
26. Zifko UA, Zipko HT, Bolton CF. Clinical and electrophysiological findings in critical illness polyneuropathy. Journal of the Neurological Sciences 1998; 159: 186-193.
27. Hund EF, Fogel W, Krieger D, DeGeorgia M, Hacke W. Critical illness polyneuropathy: clinical findings and outcomes of a frequent cause of neuromuscular weaning failure. Critical Care Medicine 1996; 24: 1328-1333.
28. Coakley JH, Nagendran K, Yarwood GD, Honavar M, Hinds CJ. Patterns of neurophysiological abnormality in prolonged critical illness. Intensive Care Medicine 1998; 24: 801-807.
29. van Mook WN, Hulsewe-Evers RP. Critical illness polyneuropathy. Current Opinion in Critical Care 2002; 8: 302-310.
30. Zochodne DW, Bolton CF, Wells GA et al. Critical illness polyneuropathy. A complication of sepsis and multiple organ failure. Brain 1987; 110 (Pt 4): 819-841.
31. Coakley JH, Nagendran K, Honavar M, Hinds CJ. Preliminary observations on the neuromuscular abnormalities in patients with organ failure and sepsis. Intensive Care Medicine 1993; 19: 323-328.
32. Hund E, Genzwurker H, Bohrer H, Jakob H, Thiele R, Hacke W. Predominant involvement of motor fibres in patients with critical illness polyneuropathy. British Journal of Anaesthesia 1997; 78: 274-278.
33. Morris C, Trinder JT. Electrophysiology adds little to clinical signs in critical illness polyneuropathy and myopathy. Critical Care Medicine 2002; 30: 2612.
34. Leijten FS, de Weerd AW. Critical illness polyneuropathy, facts and controversies. Journal of Peripheral Nervous System 1996; 1: 28-33.
35. Bolton CF, Breuer AC. Critical illness polyneuropathy. Muscle and Nerve 1999; 22: 419-424.
36. de Letter MA, Visser LH, van der Meche FG, Ang W, Savelkoul HF. Distinctions between critical illness polyneuropathy and axonal Guillain-Barre syndrome. Journal of Neurology, Neurosurgery and Psychiatry 2000; 68: 397-398.
37. Ang CW, Laman JD, Willison HJ et al. Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barre and Miller Fisher patients. Infection and Immunity 2002; 70: 1202-1208.
38. Gooch JL. AAEM case report 29: prolonged paralysis after neuromuscular blockade. Muscle and Nerve 1995; 18: 937-942.
39. Gooch JL, Suchyta MR, Balbierz JM, Petajan JH, Clemmer TP. Prolonged paralysis after treatment with neuromuscular junction blocking agents. Critical Care Medicine 1991; 19: 1125-1131.
40. Segredo V, Caldwell JE, Matthay MA, Sharma ML, Gruenke LD, Miller RD. Persistent paralysis in critically ill patients after long-term administration of vecuronium. New England Journal of Medicine 1992; 327: 524-528.
41. Hirano M, Ott BR, Raps EC et al. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992; 42: 2082-2087.
42. Rich MM, Bird SJ, Raps EC, McCluskey LF, Teener JW. Direct muscle stimulation in acute quadriplegic myopathy. Muscle and Nerve 1997; 20: 665-673.
43. Lacomis D, Giuliani MJ, Van Cott A, Kramer DJ. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Annals of Neurology 1996; 40: 645-654.
44. Larsson L, Li X, Edstrom L et al. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. Critical Care Medicine 2000; 28: 34-45.
45. Stibler H, Edstrom L, Ahlbeck K, Remahl S, Ansved T. Electrophoretic determination of the myosin/actin ratio in the diagnosis of critical illness myopathy. Intensive Care Medicine 2003; 29: 1515-1527.
46. Zochodne DW, Ramsay DA, Saly V, Shelley S, Moffatt S. Acute necrotizing myopathy of intensive care: electrophysiological studies. Muscle and Nerve 1994; 17: 285-292.
47. Helliwell TR, Wilkinson A, Griffiths RD, Palmer TE, McClelland P, Bone JM. Microvascular endothelial activation in the skeletal muscles of patients with multiple organ failure. Journal of the Neurological Sciences 1998; 154: 26-34.
48. Fenzi F, Latronico N, Refatti N, Rizzuto N. Enhanced expression of E-selectin on the vascular endothelium of peripheral nerve in critically ill patients with neuromuscular disorders. Acta Neuropathologica 2003; 106: 75-82.
49. Bolton CF. Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Critical Care Medicine 1996; 24: 1408-1416.
50. Knaus WA, Wagner DP, Draper EA et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100: 1619-1636.
51. Bednarik J, Vondracek P, Dusek L, Moravcova E, Cundrle I. Risk factors for critical illness polyneuromyopathy. Journal of Neurology 2005; 252: 343-351.
52. Langouche L, Vanhorebeek I, Vlasselaers D et al. Intensive insulin therapy protects the endothelium of critically ill patients. Journal of Clinical Investigation 2005; 115: 2277-2286.
53. Dellinger RP, Carlet JM, Masur H et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Critical Care Medicine 2004; 32: 858-873.
54. Mohr M, Englisch L, Roth A, Burchardi H, Zielmann S. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Medicine 1997; 23: 1144-1149.
55. Garnacho-Montero J, Amaya-Villar R, Garcia-Garmendia JL, Madrazo-Osuna J, Ortiz-Leyba C. Effect of critical illness polyneuropathy on the withdrawal from mechanical ventilation and the length of stay in septic patients. Critical Care Medicine 2005; 33: 349-354.
56. van der Schaaf M, Beelen A, de Groot IJ. Critical illness polyneuropathy: a summary of the literature on rehabilitation outcome. Disability and Rehabilitation 2000; 22: 808-810.
57. van der Schaaf M, Beelen A, de Vos R. Functional outcome in patients with critical illness polyneuropathy. Disability and Rehabilitation 2004; 26: 1189-1197.
58. Herridge MS, Cheung AM, Tansey CM et al. One-year outcomes in survivors of the acute respiratory distress syndrome. New England Journal of Medicine 2003; 348: 683-693.
59. de Sèze M, Petit H, Wiart L et al. Critical illness polyneuropathy. A 2-year follow-up study in 19 severe cases. European Neurology 2000; 43: 61-69.
60. Zifko UA. Long-term outcome of critical illness polyneuropathy. Muscle and Nerve. Supplement 2000; 9: S49-S52.
61. Fletcher SN, Kennedy DD, Ghosh IR et al. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Critical Care Medicine 2003; 31: 1012-1016.